Description

Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and atrophy due to the degeneration of motor neurons in the spinal cord. The severity of symptoms and age of onset can vary widely depending on the specific genetic mutation involved.

Mutation detection for SMA typically involves identifying deletions or mutations in the Survival Motor Neuron 1 (SMN1) gene, which is located on chromosome 5. The SMN1 gene encodes the survival motor neuron (SMN) protein, which is essential for the survival and function of motor neurons.

Here’s how mutation detection for SMA is commonly performed:

1. Genetic Testing: DNA testing is the primary method used to detect mutations in the SMN1 gene. This can be done using various techniques, including polymerase chain reaction (PCR), multiplex ligation-dependent probe amplification (MLPA), or next-generation sequencing (NGS).
2. Deletion Analysis: One of the most common genetic abnormalities associated with SMA is the homozygous deletion of exon 7 of the SMN1 gene. Deletion analysis using PCR or MLPA can identify the absence of exon 7 in the SMN1 gene, which confirms the diagnosis of SMA.
3. Mutation Screening: In addition to exon 7 deletions, other point mutations, insertions, or duplications in the SMN1 gene can also cause SMA. Mutation screening using PCR, sequencing, or other molecular techniques can identify these genetic abnormalities.
4. Carrier Testing: Genetic testing can also be used for carrier testing in individuals with a family history of SMA or those who are at risk of being carriers. Identifying carriers of SMA can help with family planning and genetic counseling.
5. Genotype-Phenotype Correlation: The specific genotype identified through mutation detection can provide valuable information about the expected phenotype (clinical presentation) of SMA, including the severity of symptoms and prognosis.

Mutation detection for SMA is essential for confirming the diagnosis, providing accurate genetic counseling, and guiding management and treatment decisions. Early detection through newborn screening programs and carrier testing can also help identify affected individuals and carriers before symptoms develop, allowing for early intervention and support.